ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Pfizer, Astellas Amend Research Protocols for Two Enzalutamide Trials
americanpharmaceuticalreview
August 24, 2018Pfizer and Astellas announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of Xtandi (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC).
Pharma Sources Insight January 2025
